Telomerase-Derived Peptides for Anti-Inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory drugs, such as NSAIDs and steroids, fail to fundamentally cure inflammation and often cause side effects, particularly gastrointestinal disorders, while existing peptide-based treatments like telomerase-derived peptides have not been fully explored for their anti-inflammatory properties.
Innovation Solution
Development of peptides derived from human telomerase, specifically SEQ ID NO: 101, 63, 62, 70, 71, 72, 17, 25, 42, 54, and 56, which are used in pharmaceutical and cosmetic compositions to treat a wide range of inflammatory diseases, including chronic rheumatoid arthritis, by inhibiting inflammatory pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-steroidal anti-inflammatory drugs (NSAIDs) are used to suppress COX-2 enzyme activity, then anti-inflammatory effect is improved, but COX-1 activity is suppressed causing gastrointestinal disorders
Solution Approach 1:
The invention segments the anti-inflammatory function from the harmful COX inhibition by using telomerase-derived peptides that specifically inhibit inflammatory pathways (NF-κB, AP-1, STAT3) without affecting COX-1 or COX-2 enzyme activity. This separates the therapeutic effect from the side effects of conventional NSAIDs.
Solution Approach 2:
The invention changes the mechanism of action parameter from COX enzyme inhibition to telomerase-derived peptide-mediated inhibition of inflammatory signaling pathways (NF-κB, AP-1, STAT3). This parameter change maintains anti-inflammatory efficacy while eliminating gastrointestinal toxicity associated with COX-1 inhibition.
2Ease of operation
If synthetic anti-inflammatory drugs are used to temporarily alleviate inflammation, then symptom relief is improved, but fundamental cure is not achieved and side effects occur
Solution Approach 1:
The telomerase-derived peptides act preliminarily by inhibiting the transcription factors (NF-κB, AP-1, STAT3) that control the expression of multiple inflammatory mediators simultaneously. This upstream inhibition prevents the cascade of inflammatory responses rather than merely suppressing symptoms, achieving fundamental cure potential.
3Reliability
If steroids and cortisone are used to suppress inflammation, then anti-inflammatory effect is improved, but immune system deterioration occurs
Solution Approach 1:
The telomerase-derived peptides exhibit local quality by specifically targeting inflammatory signaling pathways (NF-κB, AP-1, STAT3) without broadly suppressing the immune system. Unlike steroids that cause systemic immunosuppression, these peptides selectively inhibit only the inflammatory response while preserving normal immune function.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.